In Q2 (Apr–Jun), net sales rose to SEK 370m from SEK 331m (+~12%), while order intake increased 16% to SEK 600m (SEK 519m). Order backlog grew 18% to SEK 1,693m (from SEK 1,439m), and adjusted EBITA was SEK 12m. For the first half (Jan–Jun), net sales totaled SEK 669m, with order intake up 10% versus the prior period.
The important signal is not the sales beat; it’s that backlog is rising faster than current earnings power. That usually means one of two things: either the company is finally getting utilization leverage and the P&L is about to catch up, or it is accumulating low-margin work that ties up working capital before profitability improves. At current earnings levels, the market should care more about conversion quality than headline demand growth.
In the next 1-2 quarters, the key variable is whether backlog converts into gross margin expansion and positive cash flow. If the backlog is project-based or highly customized, the risk is that revenue will arrive with delayed EBITA, while inventory and receivables swell first. That makes the balance sheet and working-capital line items the real tell; if they deteriorate, the order growth is value-destructive rather than value-creating.
The contrarian miss is that investors may be extrapolating the order book into a structural inflection too early. With EBITA still near breakeven, the equity can rerate only if there is evidence of operating leverage, not just demand. If the next print shows margin expansion and stable cash conversion, this becomes a cleaner small-cap industrial recovery story; if not, the move is likely overdone and the shares should de-rate back to a sales-multiple screen.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25